The purpose of this study is to determine whether the Misoprostol Vaginal Insert (MVI) 200 microgram (mcg) can decrease the time to vaginal delivery compared to the Dinoprostone Vaginal Insert (DVI) 10 milligram (mg) in pregnant women requiring cervical ripening and induction of labor.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
1,358
Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Time to Vaginal Delivery During the First Hospital Admission
Time frame: Interval from study drug administration to vaginal delivery (average 24 hours)
Incidence of Cesarean Delivery During the First Hospital Admission
Time frame: Interval from study drug administration to cesarean delivery (average 24 hours)
Time to Any Delivery (Vaginal or Cesarean) During the First Hospital Admission
Time frame: Interval from study drug administration to neonate delivery (average 24 hours)
Time to Active Labor During the First Hospital Admission
Active labor was defined as progressive cervical dilatation to 4 cm with any frequency of contractions OR rhythmic, firm, adequate quality uterine contractions causing progressive cervical change occurring at a frequency of 3 or more in 10 minutes and lasting 45 seconds or more.
Time frame: Interval from study drug administration to active labor (average 12 hours)
Incidence of Pre-delivery Oxytocin During the First Hospital Admission
Percentage of participants in receipt of Oxytocin for induction after study drug removal.
Time frame: At least 30 minutes after study drug removal
Incidence of Vaginal Delivery Within 12 Hours
Time frame: Interval from study drug administration to vaginal delivery within 12 hours
Incidence of Any Delivery Within 24 Hours
Time frame: Interval from study drug administration to delivery of neonate within 24 hours
Incidence of Any Delivery Within 12 Hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Maricopa Medical Center - District Medical Group
Phoenix, Arizona, United States
Precision Trials
Phoenix, Arizona, United States
Phoenix Perinatal Associates (Scottsdale Healthcare Shea)
Scottsdale, Arizona, United States
Watching Over Mothers and Babies Foundation
Tucson, Arizona, United States
Miller's Childrens Hospital
Long Beach, California, United States
UCI Medical Center
Orange, California, United States
The Women's Clinic of Northern Colorado
Fort Collins, Colorado, United States
Christiana Care Health System (DE Center for MFM)
Newark, Delaware, United States
University of FL College of Medicine
Jacksonville, Florida, United States
Altus Research
Lake Worth, Florida, United States
...and 24 more locations
Time frame: Interval from study drug administration to delivery of neonate within 12 hours
Incidence of Vaginal Delivery Within 24 Hours
Time frame: Interval from study drug administration to vaginal delivery within 24 hours
Incidence of Vaginal Delivery
Time frame: Interval from study drug administration to vaginal delivery (average 24 hours)
Rate of Adverse Events
All adverse events were rated by the Investigator as mild, moderate or severe and classified as having no relationship, possible relationship or a probable relationship to the study drug.
Time frame: From study drug administration to hospital discharge (approximately 48-72 hours)